Hematologic Malignancy
Myelodysplastic Syndrome
CI-CAN-00001247MDN · MDSExplore in graph →
Hematologic336 active trials3 approved drugs14 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001247MDN · MDSExplore in graph →
Clinical trials
1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (307)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06138587 | Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation | recruiting | Phase 1 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT02074839 | Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | recruiting | Phase 1 | 291 | Institut de Recherches Internationales ServierOTHER | 2 | Jun 15, 2026 | clinicaltrials |
| NCT04668885 | CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS | active not recruiting | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03622788 | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07575412 | SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS | not yet recruiting | Phase 2 | 180 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07588360 | Haplo-Cord HSCT for AML/MDS | recruiting | N/A | 82 | Fujian Medical University Union HospitalOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05177211 | Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) | completed | Phase 2 | 25 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT03146871 | Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent | terminated | Phase 2 | 7 | University of Southern CaliforniaOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT04550442 | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | terminated | Phase 1 / Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06630221 | Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations | suspended | Phase 2 | 25 | Abhay Singh, MD MPHOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT02158858 | A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies | completed | Phase 1 / Phase 2 | 336 | Constellation PharmaceuticalsINDUSTRY | 9 | Jun 4, 2026 | clinicaltrials |
| NCT05800210 | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases | recruiting | Phase 2 | 20 | University of FloridaOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT00534430 | Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer | completed | Phase 2 | 30 | City of Hope Medical CenterOTHER | 0 | Jun 3, 2026 | clinicaltrials |
| NCT03964506 | Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant | recruiting | Early Phase 1 | 24 | Omar AljitawiOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05364762 | Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants | active not recruiting | Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT00544115 | Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders | active not recruiting | Phase 2 | 260 | City of Hope Medical CenterOTHER | 0 | Jun 2, 2026 | clinicaltrials |
| NCT04128748 | Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | active not recruiting | Phase 1 / Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05146739 | Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT02220985 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD | completed | Phase 2 | 84 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04250051 | Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 2 | Northwestern UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06372717 | A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS | recruiting | Phase 1 | 100 | Apollo Therapeutics LtdINDUSTRY | 2 | Jun 1, 2026 | clinicaltrials |
| NCT04195633 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | recruiting | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06681363 | Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelodysplastic Syndrome (MDS) Monitored at the Nantes University Hospital(LANA) | recruiting | — | 1,000 | Nantes University HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07616089 | Phase I Study of FXS0683 in the Treatment of Blood Tumors(FXS0683-001) | not yet recruiting | Phase 1 | 228 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT03932643 | ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant | completed | Phase 1 | 20 | University of NebraskaOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT04953897 | Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment | recruiting | Phase 1 | 18 | Taiho Oncology, Inc.INDUSTRY | 8 | May 28, 2026 | clinicaltrials |
| NCT04953910 | Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment | recruiting | Phase 1 | 27 | Taiho Oncology, Inc.INDUSTRY | 8 | May 28, 2026 | clinicaltrials |
| NCT01135329 | Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers | terminated | Phase 2 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT03434730 | Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation | completed | Phase 2 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07607327 | Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)(FORWARD) | not yet recruiting | — | 400 | CareDxINDUSTRY | 1 | May 26, 2026 | clinicaltrials |
| NCT07607418 | Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS | recruiting | Phase 2 | 20 | Ruijin HospitalOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT02632708 | Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | active not recruiting | Phase 1 | 153 | Institut de Recherches Internationales ServierOTHER | 3 | May 22, 2026 | clinicaltrials |
| NCT01962636 | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases | terminated | N/A | 200 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT02115295 | Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia | recruiting | Phase 2 | 508 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT03613532 | Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN | active not recruiting | Phase 1 | 102 | Jacqueline Garcia, MDOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04239157 | A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia | recruiting | Phase 2 | 76 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05534620 | Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics | completed | Phase 1 | 20 | medac GmbHINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT04902833 | Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms | completed | — | 18 | Massachusetts General HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05564650 | Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome | completed | Phase 1 | 6 | Thomas Jefferson UniversityOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT03326921 | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | recruiting | Phase 1 | 24 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04187703 | 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies | recruiting | Early Phase 1 | 20 | Benjamin TomlinsonOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT03600155 | Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06928662 | Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse | recruiting | Phase 1 / Phase 2 | 36 | Fred Hutchinson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | terminated | Phase 2 | 150 | Fred Hutchinson Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07566377 | Cord Blood Transplantation in Children and Young Adults With Blood Cancer | recruiting | Phase 2 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05794880 | MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing | recruiting | N/A | 40 | Medical College of WisconsinOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05088356 | Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft | active not recruiting | Phase 1 | 66 | Stanford UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05583552 | Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy(IMpress) | active not recruiting | Phase 2 | 46 | GCP-Service International West GmbHINDUSTRY | 3 | May 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 17, 2026source: clinicaltrials